跳至主要内容
临床试验/IRCT20180307038989N1
IRCT20180307038989N1招募中3 期

The effect of adding Cilostazol on cognitive deficits and symptoms of schizophrenic patients: a double-blind, randomized clinical trial

Mashhad University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 64 years(—)
性别
All

入选标准

  • Diagnosis of schizophrenia based on DSM-5 criteria
  • aged 18-64 years
  • completed consent form by the patient or his family
  • at least the eighth grade education

排除标准

  • Simultaneous psychiatric disorders
  • liver disorders
  • medical illness
  • Use of opioid substances other than cigarettes
  • A hypersensitivity reaction or any untoward side effects caused by the drug
  • Use of other interfering drugs
  • Serious cognitive impairment
  • blood or Platelet problem Contradictory with taking medication

研究者

相似试验